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Background: Cementum, a mineralized tissue lining the tooth root surface, is destroyed during the inflam-
matory process of periodontitis. Restoration of functional cementum is considered a criterion for successful
regeneration of periodontal tissues, including formation of periodontal ligament, cementum, and alveolar
bone. Short-term administration of platelet-derived growth factor (PDGF) has been shown to partially regen-
erate periodontal structures. Nonetheless, the role of PDGF in cementogenesis is not well understood. The
aim of the present study was to determine the effect of sustained PDGF gene transfer on cementum for-
mation in an ex vivo ectopic biomineralization model.
Methods: Osteocalcin (OC) promoter-driven SV40 transgenic mice were used to obtain immortalized
cementoblasts (OCCM). The OCCM cells were transduced with adenoviruses (Ad) encoding either PDGF-A,
an antagonist of PDGF signaling (PDGF-1308), a control virus (green fluorescent protein, GFP), or no treat-
ment (NT). The transduced cells were incorporated into polymer scaffolds and implanted subcutaneously
into severe combined immunodeficient (SCID) mice. The implants were harvested at 3 and 6 weeks for his-
tomorphometric analysis of the newly formed mineralized tissues. Northern blot analysis was performed to
determine the expression levels of mineral-associated genes including bone sialoprotein (BSP), OC, and osteo-
pontin (OPN) in the cell-implant specimens at 3 and 6 weeks.
Results: The results indicated mineralization was significantly reduced in both the Ad/PDGF-A and
Ad/PDGF-1308 treated specimens when compared to the NT or Ad/GFP groups at 3 and 6 weeks (P <0.01).
In addition, the size of the implants treated with Ad/PDGF-A and Ad/PDGF-1308 was significantly reduced
compared to implants from Ad/GFP and NT groups at 3 weeks (P <0.05). At 6 weeks, the size of implants
and mineral formation increased in NT, Ad/GFP, and Ad/PDGF-A groups, while the Ad/PDGF-1308 treated
implants continued to decrease in size and mineral formation (P <0.01). Northern blot analysis revealed that
in the Ad/PDGF-A treated implants OPN was increased, whereas OC gene expression was downregulated
at 3 weeks. In the Ad/PDGF-1308 treated implants, BSP, OC, and OPN were all downregulated at 3 weeks.
At 3 weeks, the Ad/PDGF-A treated implants contained significantly higher multinucleated giant cell (MNGC)
density compared to NT, Ad/GFP, and Ad/PDGF-1308 specimens. The MNGC density in NT, Ad/GFP, and
Ad/PDGF-A treated groups reduced over time, while the Ad/PDGF-1308 transduced implants continued to
exhibit significantly higher MNGC density compared with the other treatment groups at 6 weeks.
Conclusions: The results showed that continuous exposure to PDGF-A had an inhibitory effect on cemen-
togenesis, possibly via the upregulation of OPN and subsequent enhancement of MNGCs at 3 weeks. On
the other hand, Ad/PDGF-1308 inhibited mineralization of tissue-engineered cementum possibly due to the
observed downregulation of BSP and OC and a persistence of stimulation of MNGCs. These findings suggest
that continuous exogenous delivery of PDGF-A may delay mineral formation induced by cementoblasts,
while PDGF is clearly required for mineral neogenesis. J Periodontol 2004;75:429-440.
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P
eriodontitis is a major cause of tooth loss in
adults. The disease is characterized by the des-
truction of periodontal tissues including peri-
odontal ligament, cementum (a mineralized tissue
lining the tooth root surface), and alveolar bone.
Proper formation of cementum is required for devel-
opment of a functional periodontal ligament. Fur-
thermore, the presence of healthy cementum is
considered to be an important criterion for predictable
restoration of periodontal tissues.1 However, the mech-
anisms controlling development and regeneration of
this tissue are not well understood. Platelet-derived
growth factor (PDGF) has been shown to be involved
in tooth development and cementogenesis.2,3 The
ability to provide sustained delivery of PDGF via gene
transfer allows for the study of mechanisms controlling
cementogenesis.
PDGF is an important stimulator of cellular chemo-
taxis, proliferation, and matrix synthesis.4-6 It also
exhibits anti-apoptosis activity.7 The biological activities
of PDGF are mediated through two intrinsic phospho-
tyrosine kinase receptors (PDGFαR and PDGFβR) that
induce several sets of signaling molecules.8 Applica-
tion of PDGF alone or in combination with insulin-like
growth factor results in partial regeneration of periodon-
tal tissues in preclinical and clinical investigations.9-12
Results from studies using recombinant growth factors
(GFs) to promote periodontal wound healing have not
been as successful as hoped and have revealed limi-
tations in time of exposure and bioavailability.13 In
order to prolong GF activity, gene therapy has been
evaluated in several wound healing situations, including
models associated with skin, bone, and periodontal
tissues.14-16 Our group previously reported that the
application of adenovirus encoding PDGF (Ad/PDGF)
to cells derived from the periodontium stimulates mito-
genesis and proliferation of multiple cell types in
vitro.17,18 Using this approach, expression of PDGF
was prolonged at both RNA and protein levels for at
least a week. In addition, Ad/PDGF gene transfer re-
sulted in sustained tyrosine kinase phosphorylation
and downregulation of the growth arrest specific (gas)
gene product PDGFαR for at least 96 hours.19 Deliv-
ery of PDGF-B transgenes to human gingival fibroblasts
stimulated cell proliferation, migration, and defect fill in
an ex vivo three-dimensional wound model.20 Most
recently, in vivo gene transfer of Ad/PDGF-B was shown
to stimulate periodontal tissue repair.21
Biodegradable polymers have great potential for the
use in delivery of GFs to wound healing sites.22,23
Three-dimensional polymer scaffolds provide a suitable
environment for osteogenic cell proliferation and dif-
ferentiation.24,25 A gas foaming/particulate leaching
approach has been implemented to fabricate porous
(>95%) scaffolds from synthetic copolymers of lactide
and glycolide (PLGA)26 and has been used to success-
fully regenerate bone and periodontal tissues.25,27,28
Cementoblasts seeded in PLGA scaffolds under either
static or dynamic conditions in vitro and implanted
into SCID mice subcutaneously exhibit mineral for-
mation.29 Furthermore, transplantation of cemento-
blasts in PLGA scaffolds to periodontal fenestration
defects promotes tissue repair.30
The establishment of a cementoblast cell line31
enables us to study the effect of PDGF gene transfer
on cementoblasts in vivo. The purpose of this study
was to test the biological effects of ex vivo gene trans-
fer of PDGF-A or an antagonist (PDGF-1308) on the
formation of cementum in an ectopic biomineralization
model in SCID mice. Also, the expression of mineral
associated genes were determined. Results from these
investigations will enhance our knowledge of the mech-
anisms controlling development, maintenance, and
regeneration of cementum.
MATERIALS AND METHODS
Construction of Recombinant Adenoviruses
The construction of adenoviruses (Ad2 driven by the
cytomegalovirus promoter [CMV]) encoding PDGF-A
(Ad/PDGF-A) and its dominant negative mutant (Ad/
PDGF-1308) has been previously described.17 Briefly,
the full-length murine PDGF-A or PDGF-1308 cDNA
(kind gifts of Dr. C.D. Stiles, Boston, Massachusetts)
was subcloned into a shuttle plasmid pAD2/CMV/SVIX§
under the control of CMV promoter. Recombinant viral
plaques were identified, selected, and purified. Titers of
the viral stocks were determined on 293 cells by plaque
assay and expressed as the number of plaque forming
units (pfu) per ml.
Cell Culture
The establishment of an immortalized murine cemen-
toblast (OCCM) cell line has been reported in detail
previously by D’Errico et al.31 The OCCM cell line
was maintained in Dulbecco’s modified Eagle medium
(DMEM), supplemented with 10% fetal calf serum¶
(FCS), L-glutamine (2 mM), and antibiotics (100
units/ml penicillin and 100 µg/ml streptomycin) in a
humidified atmosphere of 5% CO2 in air at 37°C.
Polymer Scaffold Fabrication
Poly (DL-lactic-co-glycolic acid; PLGA) three-dimensional
scaffolds were processed into porous foams by an estab-
lished solvent-casting, particulate-leaching technique
as described previously.32,33 These composites were
cut into 5 × 5 × 2 mm blocks, sterilized with UV light, and
stored until used. The resultant PLGA blocks were
porous scaffolds containing 95% porosity and pore sizes
ranging from 250 to 425 µm (Fig. 1A).
§ Genzyme Corp., Cambridge, MA.
 Gibco BRL Life Technologies, Inc., Grand Island, NY.
¶ Gemini Bio-Products, Woodland, CA.
431
J Periodontol • March 2004 Anusaksathien, Jin, Zhao, Somerman, Giannobile
Ex Vivo Transduction of OCCM Cells by PDGF-A
or PDGF-1308 Transgenes and Implantation
OCCM cells (passage #16) were plated at 1 × 106 cells/
plate and grown to confluence for 3 days (8 × 106 cells/
plate). The expression of mineral-related genes includ-
ing bone sialoprotein (BSP) and OC was confirmed by
Northern blot analysis before use in each experiment.
The cells were transduced with 100 MOI of Ad/PDGF-A,
Ad/PDGF-1308, Ad/GFP, or no treatment (NT) in serum-
free conditioned medium. After incubation and shak-
ing every hour for 5 hours, the medium was replenished
with DMEM supplemented with 10% FCS and further
incubated overnight at 37°C. The adenoviral-treated or
non-treated cells were incorporated into the PLGA scaf-
folds at 1 × 106 cells/sponge and cells allowed to attach
to the polymer by incubation overnight at 37°C. The
cell incorporated polymers were then implanted sub-
cutaneously in immunodeficient (SCID) mice (Fig. 1B).
The surgical procedure has been described previously
in detail by Jin et al.29 The management of the ani-
mals was performed in accordance with a protocol
approved by the Committee on the Care and Use of
Animals at the University of Michigan. Four blocks of
cell-implants were placed in the dorsum of
each animal. Assessments included histo-
logical evaluation (n = 3 implants/group) and
RNA analysis by reverse transcription poly-
merase chain reaction (RT-PCR) and North-
ern blot (n = 3 implants/group). The implants
were harvested at 3 and 6 weeks and fixed
in Bouin’s solution (0.9% picric acid, 9%
vol/vol formaldehyde, and 5% acetic acid).#
The specimens were then decalcified with
10% vol/vol acetic acid, 4% vol/vol formalde-
hyde, 0.85% NaCl for 2 to 3 weeks, cut in the
center, and embedded in paraffin. The spec-
imens were sectioned at 5 µm and stained
with hematoxylin and eosin (H&E).
RNA Extraction from Polymer-Cell
Implants
For RNA analyses, after removal of implants,
specimens were immediately snap frozen
using liquid nitrogen. Each specimen was
ground into small pieces and transferred to
an Eppendorf tube. The tissue pellet was pre-
cipitated by adding 1 ml of Trizol, vortexed
for 30 minutes at room temperature, and
centrifuged at 10,000 rpm for 10 minutes at
4°C. The supernatant was collected and total
RNA was extracted for evaluation by RT-PCR
or Northern blot analysis (see below).
Sustained Expression of PDGF Genes
In Vivo Using RT-PCR
Reverse transcription polymerase chain reac-
tion was performed to determine the prolonged
expression of PDGF genes by adenovirus infection in
vivo. One µg of total RNA extracted from PLGA-cell
implants at 3 and 6 weeks was reverse transcribed
using a kit.** A primer pair was specifically designed
to determine the expression of Ad/PDGF-A and
Ad/PDGF-1308. The forward primer located at the
3′ end of the PDGF-A or PDGF-1308 gene was 5′-
TCGCAGGAAGAGAAGTATTG-3′. The reverse primer
included the adenovirus backbone for both constructs
was 5′-CATCAATGTATCTTATCACGCG-3′. Endoge-
nous PDGF-A expression was also performed using a
primer pair 5′-CCTGTGCCCATTCGCAGGAAGAG-3′
and 5′-TTGGCCACCTTGACACTGCG-3′. The house-
keeping gene, β-actin, was used to assess the load-
ing of the samples. A total of 25 µl of PCR reaction
was mixed with 5 µl of RT product, PCR buffer (10
mM Tris–HCl, pH 9.0, 50 mM KCl, and 0.1% Triton X-
100), 0.2 mM dNTPs, 2.5 mM MgCl2, 20 pM of each
primer, 0.5 unit of Taq DNA polymerase†† using a
Figure 1.
Cementum engineering in three-dimensional polymer scaffolds. A) Images depict
microscopic structure of PLGA scaffold and OCCM cells seeded into the scaffold.
The PLGA scaffold exhibits open-pore structures allowing cell penetration and
attachment.A representative phase contrast image depicts the PLGA seeded with
OCCM transduced with Ad/GFP 48 hours after transduction.The fluorescent image
shows the corresponding OCCM cells expressing green fluorescent protein in the
scaffold. B) Diagram depicts OCCM transduced with adenovirus encoding PDGF-A,
PDGF-1308, green fluorescent protein, or NT 24 hours after transduction.The
transduced cells were seeded into PLGA polymer scaffold and implanted into SCID
mice (n = 4 implants/animal).
# Polysciences, Warrington, PA.
** Retroscript, Ambion, Inc., Austin, TX.
†† Promega Co., Madison, WI.
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thermocycler 9600.‡‡ The PCR conditions for detect-
ing the expression of adenoviruses encoding PDGF-A
and PDGF-1308 were 94°C for 2 minutes, 35 cycles
of 94°C for 30 seconds, 60°C for 30 seconds, followed
by 72°C for 45 seconds. PCR conditions for detection
of endogenous PDGF-A and β-actin were the same,
except only 30 cycles were performed. The expected
PCR product was 638 bp for both Ad/PDGF-A and
Ad/PDGF-1308, 226 bp for endogenous PDGF-A, and
248 bp for β-actin.
Histomorphometry
Histomorphometric analysis was used to determine the
size dimensions of the implants from the gross speci-
mens at 3 and 6 weeks using a computer-assisted
image analysis program. The size of the implants, the
total area of mineralization, and density of formed min-
eral were evaluated from standardized images captured
from the 3- and 6-week H&E-stained sections at 20×
magnification. A single masked calibrated examiner
(OA) evaluated the size of the specimens and areas of
mineralization using a software program§§ and demon-
strated a pre- and post-study calibration intraexaminer
error of <5%. Because the implants were sectioned in
half at the center of the specimen before paraffin
embedding, the total area of specimen was determined
two-dimensionally by drawing a perimeter line along a
representative section of each implant. Percentage of
mineral to total tissue (density) of the implants was
determined by dividing area of mineralization by total
area of the specimen as previously described.29 In add-
ition, the number of multinucleated giant cells (MNGCs)
was counted in each specimen at 3 and 6 weeks. Cell
density was determined by dividing cell number by the
total tissue area for each specimen. The specimens
were uncoded and mean and standard error measure-
ments were calculated for each treatment group. One-
way analysis of variance (ANOVA) and Tukey multiple
comparison tests were utilized to evaluate the difference
in the size of the specimens, area of mineralization,
mineral density, and MNGC density between groups.
Northern Blot Analysis
To determine the expression of genes regulated by PDGF
in vivo, Northern blot analysis was performed. Ten µg
of total RNA was denatured, separated in a 6% formalde-
hyde/1.2% agarose gels, transferred onto a nylon mem-
brane,  and immobilized. Probes used for Northern blot
analysis included murine OC cloned into pSP6534 (a gift
of Dr. J. Wozney, Genetic Institute, Boston, Massachu-
setts), 1 kb PCR product of BSP, and osteopontin (OPN)
cloned into PCR II vector (gifts of Drs. M. Young and L.
Fisher NIDCR/NIH, Bethesda, Maryland).35,36 The blots
were then hybridized with 32P-labeled probes generated
from randomly primed cDNA¶¶ and exposed to films
with intensifying screens at −70°C for 6 to 24 hours. An
18S RNA probe was used to evaluate the relative load-
ing of RNA samples.
Cell Survival Analysis
To determine the ability of Ad/PDGF-A or Ad/PDGF-
1308 gene transfer to induce apoptosis in OCCM cells,
caspase 3/7 activities were assayed using a caspase
3/7 kit.†† OCCM cells were plated at 2 × 104 cell/well
in a 96 well plate and incubated O/N at 37°C. The pro-
tocol for adenovirus transduction with 10 and 100 MOI
of Ad/PDGF-A or Ad/PDGF-1308 was similar to that
described above. However, the use of Ad/GFP inter-
fered with fluorescent wavelength in the system, there-
fore Ad/luciferase (adenovirus encoding luciferase driven
by the CMV promoter; kind gift of Selective Genetics,
Inc., San Diego, California) was utilized in these exper-
iments. Induction of apoptosis in OCCM cells by treat-
ment with 100 µM of the chemotherapeutic agent,
etoposide, for 16 hours was used as a positive control.
Each experiment was performed in duplicate. Caspase
3/7 activities were assayed following the manufacturer’s
protocol 24 and 48 hours following Ad/PDGF-A or
Ad/PDGF-1308 gene transfer or 20 ng/ml of rhPDGF-
AA## application. In addition, terminal deoxynucleotidyl
transferase-mediated dUTP nick-end labeling (TUNEL)
staining was performed on 3- and 6-week specimens
to determine induction of apoptosis in tissue specimens
following gene transfer of PDGF-A or PDGF-1308.
RESULTS
Sustained Expression of PDGF Genes 
in OCCM-PLGA Implants
Images depicting the microscopic structure of PLGA
scaffold-OCCM implants transduced by Ad/GFP for
48 hours are presented in Figure 1A. An open pore struc-
ture of the PLGA scaffolds allowed for penetration and
adherence by the transduced cells as shown by phase
contrast and fluorescence microscopy. Having estab-
lished that these scaffolds provide a positive environment
for cells transduced by adenoviruses, the cells were com-
bined with PLGA and implanted in SCID mice. Implant
specimens retrieved at 3 and 6 weeks demonstrated pro-
longed expression of Ad/PDGF-A and Ad/PDGF-1308
as analyzed by RT-PCR (Fig. 2). No such expression
was detectable in the NT and Ad/GFP groups. Endoge-
nous PDGF-A expression was detected at similar levels
in all OCCM-implant groups for up to 6 weeks (Fig. 2).
Descriptive Histology
The gross appearance of the implants and measure-
ments of the implant sizes at 3 and 6 weeks are shown
‡‡ Perkin Elmer, Norwalk, CT.
§§ Image Pro Plus, Media Cybernetics, Silver Spring, MD.
  Duralon, Stratagene, Inc., La Jolla, CA.
¶¶ Rediprime, Amersham, Arlington Heights, IL.
## Upstate Biotechnology, Lake Placid, NY.
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Figure 2.
RT-PCR analysis of prolonged PDGF-A,Ad/PDGF-A, and Ad/PDGF-1308
gene expression in vivo. RNA extracted from each implant group
was subjected to RT-PCR with primer pairs specifically designed
for detecting the expression of PDGF-A and PDGF-1308 transgenes,
and endogenous PDGF-A in comparison to β-actin at 6 weeks. PCR
products were analyzed on an ethidium bromide-stained gel.
Endogenous expression of PDGF-A was detected at similar levels
for all treatment groups for up to 6 weeks.Transcripts for Ad/PDGF-A
and Ad/PDGF-1308 were noted up to 6 weeks, and were not detected
in NT and Ad/GFP-treated implants (n = 3 animals/group).
in Figures 3A and 3B. Significantly smaller implant
dimensions were observed for the Ad/PDGF-A and
Ad/PDGF-1308 treated specimens compared with NT
and Ad/GFP implants at 3 weeks (P <0.05). All of the
implants increased in size from 3 to 6 weeks, except
for the Ad/PDGF-1308 treated implants which were
significantly smaller when compared with NT or Ad/
GFP groups by 6 weeks (P <0.01).
The histological appearance of implants retrieved
from SCID mice is shown in Figure 4. Significant evi-
dence of immature mineral formation (woven-like
appearance) was detected in the NT and Ad/GFP
groups at 3 weeks, with increased mineral formation
6 weeks post-implantation. Minimal to no mineral
formation was detected in both the Ad/PDGF-A (n =
2/3) and Ad/PDGF-1308 (n = 3/3) treated implants
at 3 weeks, but by 6 weeks there was evidence of
mineral neogenesis. The Ad/PDGF-A treated implants
exhibited mature mineral formation at 6 weeks, while
Ad/PDGF-1308 specimens revealed a paucity of
mineral (Fig. 4).
Multinucleated giant cell infiltration was present along
the lattices in all the samples at 3 weeks (Fig. 5A).
Cell density analyses revealed that Ad/PDGF-A and
Ad/PDGF-1308 treated groups contained significantly
higher MNGC density versus both control groups at
3 weeks (P <0.001, Fig. 5B), and the Ad/PDGF-A
treated implants exhibited greater MNGC density versus
the Ad/PDGF-1308 group at this time point (P <0.05).
At 6 weeks, the number of MNGCs in the Ad/PDGF-A
treated implants decreased and was comparable to NT
and Ad/GFP specimens; however, the Ad/PDGF-1308
treated implants showed continued elevation of MNGC
density when compared with the other treatment groups
(P <0.05).
Histomorphometry
Histomorphometric analyses of the total area of miner-
alization, and mineral density at 3 and 6 weeks post-
implantation are shown in Figure 6. The total area of
mineralization was significantly less in the Ad/PDGF-A
and Ad/PDGF-1308 groups compared to NT and Ad/
GFP specimens at both 3 weeks (P <0.001) and 6 weeks
(P <0.05; Fig. 6A). The mineral density of the Ad/PDGF-
A group was significantly less than the control groups
at 3 weeks (P <0.01), while at 6 weeks mineral density
was similar to controls (Fig. 6B). Ad/PDGF-1308 treat-
ment resulted in significantly reduced mineralization
that was sustained for the 6-week observation period
(P <0.05; Fig. 6B).
Expression of Mineral-Associated Genes in
Cementoblasts in Response to PDGF Gene Transfer
To determine the effect of PDGF-A and PDGF-1308 on
the modulation of cementum neogenesis in vivo, the
expression of genes associated with mineral forma-
tion, including BSP, OC, and OPN, were evaluated in
implants retrieved at 3 and 6 weeks using Northern blot
analysis (Fig. 7). The levels of gene expression were
normalized to 18S RNA to compensate for loading of
RNA. At 3 weeks, BSP expression levels were similar
in NT, Ad/GFP, and Ad/PDGF-A groups, while RNA
from Ad/PDGF-1308 treated implants lacked transcrip-
tion for BSP. Expression of OC was downregulated
in implants from Ad/GFP and Ad/PDGF-A when com-
pared to implants from NT, whereas no detectable level
of OC mRNA was observed in the AD/PDGF-1308 im-
plants at 3 weeks. Ad/PDGF-A exposure upregulated
the expression of OPN, while Ad/PDGF-1308 reduced
OPN gene expression at 3 weeks. By 6 weeks, gene
expression of BSP, OC, and OPN was relatively similar
in samples from all groups.
OCCM Cell Apoptosis
PDGF has been reported to be a cell survival factor.7
Therefore, we sought to determine whether any of the
results observed were due to Ad/PDGF-A or Ad/PDGF-
1308 mediated OCCM cell death. Apoptosis was eval-
uated in vitro using caspase 3/7 activities and in tissue
samples using TUNEL staining. The caspase 3/7 assay
was performed at 24 and 48 hours following trans-
duction of OCCM cells with 10 and 100 MOI of Ad/Luc,
Ad/PDGF-A, Ad/PDGF-1308, 20 ng/ml rhPDGF-AA,
or NT. The levels of caspase 3/7 activities were not
significantly different among any of the treatment
groups at any time point for both doses of adenovirus
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as compared to the NT control (data not shown).
However, all groups exhibited decreased caspase 3/7
activities compared to etoposide treatment (positive
control). In addition, no difference in TUNEL staining
was noted among any of the groups (data not shown).
DISCUSSION
Several animal models indicate that bolus delivery of
PDGF results in significant regeneration of new
cementum, periodontal ligament, and alveolar bone.9-
11 To our knowledge, this is the first in vivo study
directed toward determining the long-term effect of
PDGF on cementum formation. In the present study,
the long-term effect of PDGF-A gene delivery on
cementum formation was examined using three-
dimensional scaffolds implanted in vivo. The reduc-
tion of implant size in the Ad/
PDGF-A treated implants at 3 weeks
was unexpected since cemento-
blasts exposed to either Ad/
PDGF-A or PDGF-AA protein in
vitro exhibited enhanced prolifera-
tion versus untreated cells.18 One
possible explanation for this appar-
ent discrepancy in implant size may
be related to the large number of
MNGCs associated with the Ad/
PDGF-A treated implants (Fig. 5A).
Platelet-derived growth factor is
a potent chemotactic factor for
macrophages.37 Also, high levels of
PDGF gene expression have been
detected in macrophages that infil-
trate soft tissues surrounding failing
implants derived from patients
receiving total hip replacement.38
Similarly, Salcetti et al. reported ele-
vations of PDGF in gingival crevic-
ular fluid obtained from failing
dental implants as compared to
healthy osseointegrated fixtures.39
Furthermore, significantly higher
levels of PDGF were detected in
tissue derived from chronic peri-
odontitis lesions compared to
healthy sites.40 Platelet-derived
growth factor has been shown to
stimulate osteoclastic bone resorp-
tion directly.41 In addition, PDGF
secreted by osteoclasts was reported
to inhibit osteoblastic differentia-
tion.42 Therefore, the presence of
MNGCs in the Ad/PDGF-A treated
implants may have had a negative
effect on cementoblast differentia-
tion and matrix formation.
Histomorphometric analysis showed that mineral-
ization was reduced at 3 weeks in the Ad/PDGF-A
treated implants as compared to NT and Ad/GFP
groups. In support of this finding, continuous exposure
to PDGF inhibited both osteoblast- and cementoblast-
mediated mineral nodule formation in vitro and in these
in vitro studies this was attributed to increased prolif-
eration, followed by decreased cell differentiation.43,44
However, exposure of cementoblasts to PDGF for 24 or
72 hours in vitro prior to implantation did not block
mineral formation in implants retrieved at 6 weeks43
and in osteoblasts in vitro pulse treated with PDGF,
mineral nodule formation was enhanced.44 Short-term
treatment with PDGF stimulated DNA synthesis in
osteoblasts without inhibiting differentiating function
of osteoblasts, whereas continuous application of PDGF
Figure 3.
Macroscopic appearance and size of retrieved tissue-engineered implants. A) Standardized image
shows the macroscopic appearance of PLGA-OCCM implants following gene transfer of Ad/GFP,
Ad/PDGF-A,AD/PDGF-1308, or NT at 3 and 6 weeks post-implantation. B) Histomorphometric
analysis of the peri-implant areas (mm2) revealed that Ad/PDGF-A and Ad/PDGF-1308 treated
implants were significantly smaller than the NT and Ad/GFP treated groups at 3 weeks (*P <0.05;
†
P <0.01).At 6 weeks, implant size increased for all groups except the Ad/PDGF-1308 group.The
Ad/PDGF-1308 treated specimens were significantly smaller when compared with control
groups (P<0.01) (n = 3 animals/group).
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blocked osteoblast differentiation in vitro.44 Ad/PDGF-
A treated implants exhibited mineral neogenesis at
6 weeks, albeit at lower levels than NT (Fig. 6). Results
from previous studies42,44 and those reported here
suggest that brief exposure of cementoblasts to PDGF
might enhance formation of mineral, while continuous
exposure is inhibitory by blocking cementoblast
differentiation in vivo. Further studies are required to
determine the mechanism(s) controlling PDGF regu-
lation of mineralization in vivo and,
furthermore, if this is related to
biphasic responses or decreased
levels of PDGF expressed at 6
weeks in this model.
Northern analysis of genes as-
sociated with mineral formation
showed that OPN was increased
in Ad/PDGF-A treated implants
at 3 weeks, while OC was slightly
downregulated compared with NT
and Ad/GFP groups (Fig. 7). At
6 weeks, the levels of OPN, BSP,
and OC expression in the
Ad/PDGF-A treated implants were
similar to the other three groups.
These results parallel our in vitro
studies where we reported that
application of PDGF-AA or PDGF
gene transfer to cementoblasts
resulted in up-regulation of OPN
and a reduction of BSP and OC
gene expression.18,43 Existing data
support the role for OPN as a reg-
ulator of matrix mineralization.
Bones from OPN-deficient mice
exhibit an increased mineral con-
tent and crystal size.45 Interest-
ingly, OPN has been reported to
promote macrophage migration,
attachment, and function.46 In this
regard, the increase in the number
of MNGCs associated with the
PLGA scaffolds in the Ad/PDGF-
A treated group compared to the
other groups may be related to the
direct effect of PDGF as discussed
above, as well as PDGF-mediated
induction of high OPN levels (Figs.
5A and B). Therefore, inhibition of
mineral neogenesis in Ad/PDGF-
A treated implants at 3 weeks
might be mediated through the
upregulation of the OPN gene.
Collectively, high levels of PDGF
produced during the first 3 weeks
of implantation and induction of
OPN expression by PDGF are likely to be responsible
for the recruitment of MNGCs, mimicking chronic inflam-
mation.47 This, in turn, inhibited cementoblast differen-
tiation as evidenced by decreased expression of OC, a
marker of cementoblast differentiation and subsequently
limited biomineralization. By 6 weeks, PDGF production
appeared to be reduced and expression of genes asso-
ciated with mineral formation were similar to those of
untreated samples, thus allowing for mineral formation.
Figure 4.
The effect of PDGF-A and PDGF-1308 transgenes on tissue-engineered cementum at 3 and
6 weeks in vivo. Mineralization was minimal to none in the Ad/PDGF-A and Ad/PDGF-1308 treated
implants, whereas immature mineral formation was present in the NT and Ad/GFP implants at
3 weeks (left panels). Mineral formed was laced-like, with no hematopoietic or fatty tissue.At
6 weeks, mineral formation progressed in all groups, except the Ad/PDGF-1308 specimens,
where minimal mineral formation was noted (right panels). (H&E; original magnification ×100;
n = 3 animals/group).
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The mechanisms by which PDGF controls the ex-
pression of BSP and OC genes in cementoblasts are not
well characterized. One of the possible explanations is
that PDGF directly or indirectly exerts its effects on
BSP and OC gene expression via up-regulation of trans-
forming growth factor (TGF)-β.37,48 TGF-β’s effects
on BSP and OC gene expression in cementoblasts
and osteoblasts are similar to those of PDGF; however,
TGF-β did not promote cementoblast proliferation in
vitro.43,49 It has been shown that the rat BSP promoter
contains a TGF-β activation element that is involved in
induction of BSP in response to TGF-β.50 After trig-
gering of receptor phosphorylation, PDGF transduces
signals from the cell surface to the
nucleus by activating the extracel-
lular signal-regulated kinase (ERK)
via the Ras/Raf/MEK/ERK cascade
in osteoblasts.51 It has been shown
that TGF-β suppresses OC gene
expression via the ERK pathway
in the human osteoblast culture
system.52 We have also shown that
application of Ad/PDGF-A resulted
in sustained phosphorylation of
PDGFαR as well as prolonged phos-
phorylation of the downstream
ERK1/2 signaling pathway.19 There-
fore, it is possible that down regu-
lation of OC expression by PDGF
gene transfer is mediated via ERK
signaling in cementoblasts. The
signaling mechanisms involved in
PDGF regulation on genes associ-
ated with matrix protein expression
await further studies.
PDGF-1308 is a dominant neg-
ative mutant that possesses anta-
gonistic effects through formation
of inactive and unstable hetero-
dimers with wild type PDGF-A or
-B chains.53 The biological activ-
ities of PDGF are exerted through
the autophosphorylation of its
tyrosine kinase receptor dimeriza-
tion.8 It has been shown that Ad/
PDGF-1308 completely abolishes
the activated state of PDGFαR by
blocking phosphorylation of the
receptor that disrupts PDGF bio-
activity.19 In addition, cells trans-
duced with PDGF-1308 exhibit a
decrease in cell proliferation.54 In
the present study, the implant size
in the Ad/PDGF-1308 treated im-
plants continued to decrease even
at 6 weeks and was unrelated to
apoptosis (as determined by TUNEL staining and cas-
pase 3/7 activities). Therefore, continued reduction of
implant size in the Ad/PDGF-1308 treated group may
be mediated through the inhibition of OCCM prolifer-
ation. Also, the growth inhibitory effect in the
Ad/PDGF-1308 treated implants may be governed in
part by the persistence of MNGCs during the 6-week
observation period.
The mechanism involved in the inhibition of mineral
formation mediated by Ad/PDGF-1308 clearly differed
from that noted with Ad/PDGF-A treatment. The anta-
gonistic activities of PDGF-1308 may not only inhibit
cell proliferation, but also reduce matrix formation.
Figure 5.
A) Images depict infiltration of MNGCs in the OCCM-PLGA implants following NT, Ad/PDGF-A,
or Ad/PDGF-1308 gene transfer at 3 weeks.Arrow heads indicate MNGCs. MNGC density at 3
and 6 weeks was determined by dividing total cell numbers by total cross-sectional area for each
implant. B) Cell density analyses revealed that Ad/PDGF-A and Ad/PDGF-1308 treated groups
contained significantly higher MNGC density versus both control groups at 3 weeks (†P <0.001),
the Ad/PDGF-A treated implants exhibited greater MNGC density compared to the Ad/PDGF-1308
group at 3 weeks (*P <0.05).At 6 weeks, only Ad/PDGF-1308 treated implants contained
significantly higher cell density compared to NT,Ad/GFP, or Ad/PDGF-A groups (*P <0.05). (H&E;
400× magnification).
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Figure 6.
Histomorphometric analysis of mineral neogenesis in OCCM-PLGA implants following gene transfer of Ad/GFP, Ad/PDGF-A,Ad/PDGF-1308, or NT.
A) Total area of mineral formation and B) Percentage of mineral density at 3 and 6 weeks measured by computer-assisted image analysis.The
percentage of mineral density equals the total area of mineral formation divided by total area of implant.The data represent mean and standard error
of mean for each treatment group. Significantly less mineralization was seen in the Ad/GFP, Ad/PDGF-A, or Ad/PDGF-1308 groups compared to NT at
3 and 6 weeks (*P <0.05, †P <0.01, ‡P <0.001). Percentage of mineral density was significantly less in the Ad/PDGF-A and Ad/PDGF-1308 groups as
compared to the NT or Ad/GFP treated groups at 3 weeks. However, mineral density of the Ad/PDGF-A treated groups was comparable to that of the
control groups at 6 weeks, while the Ad/PDGF-1308 group remained significantly less versus NT group (n = 3 animals/group).
Northern analysis showed that expression of BSP and
OC were dramatically downregulated in the Ad/PDGF-
1308 treated implants at 3 weeks. Evidence to date
suggests that BSP is a nucleator of hydroxyapatite
crystal formation,55,56 while OC appears to play a role
in early phases of mineralization and in regulation of
crystal growth.56,57 Thus, suppression of mineral for-
mation in the Ad/PDGF-1308 treated implants at
3 weeks may be mediated by inhibition of BSP and OC
expression. Also, elevated levels of MNGC density were
observed in the Ad/PDGF-1308 treated implants as
compared to the NT and Ad/GFP groups at 3 and
6 weeks (Fig. 5B). As stated above, PDGF is a potent
chemotactic factor for macrophages.37 Although OPN
expression was slightly downregulated in the Ad/
PDGF-1308 treated group, one possible explanation,
while highly speculative, is that PDGF-1308 might
recruit MNGCs into the scaffolds without the ability of
the cells to recognize the difference in the amino acid
change in the PDGF-1308 molecule. This may be one
of the contributing factors that resulted in reduced
mineralization induced by cementoblasts infected by
Ad/PDGF-1308. These results suggest that endoge-
nous PDGF plays an important role in cementoblast
proliferation and differentiation, although there may
be other direct or indirect functions of PDGF on cemen-
toblast activity that remain to be determined.
Although it is difficult to measure the actual pro-
duction of PDGF-AA protein in this in vivo model,
we have shown prolonged expression of Ad/PDGF-A
and Ad/PDGF-1308 genes up to 6 weeks by RT-PCR
(Fig. 2). The results suggest that transduced OCCM
cells were able to produce biologically active PDGF
proteins. It has been estimated that cells transduced
with Ad/PDGF-A produce ∼200 ng of PDGF-AA per
106 cells per day.19 This level of PDGF-AA production
appears to be sufficient to exert biological effects on
the surrounding host cells; e.g., MNGCs that infiltrate
the cell-implants presumably through gradient dif-
fusion of PDGF. Additional studies will be needed to
elucidate the release characteristics of transduced
cells by adenovirus in vivo. Furthermore, we acknow-
ledge the limitations of this ectopic model for the
generation of tissue-engineered cementum. The con-
tribution of the tooth root surface cannot be under-
estimated in terms of the signaling mechanisms
controlling cementogenesis. We have recently reported
the behavior of these cloned cementoblasts in peri-
odontal wounds.30 Indeed, the tissue-engineered
cementum forms mineral in the position of the sup-
porting bone as well as early evidence of root-lining
tissue neogenesis. Future studies will examine the
ability of genetically-modified cementoblasts to pro-
mote periodontal tissue regeneration.
In summary, the effect of long-term delivery of
PDGF-A and PDGF-1308 via gene transfer on cemen-
tum formation was examined in three-dimensional
scaffolds implanted subcutaneously in vivo. PDGF-A
appears to initially inhibit growth and biomineraliza-
tion at 3 weeks, with recovery from these effects at
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6 weeks. This result might be governed through the
upregulation of OPN at 3 weeks and the dose of PDGF
delivered by gene transfer. In contrast, the PDGF anta-
gonist (PDGF-1308) inhibited cell growth and mineral
formation for the entire 6-week study. This may be
mediated by suppression of BSP and OC gene expres-
sion as well as inhibition of endogenous PDGF and
persistent stimulation of MNGCs noted with OCCM-
polymer implants. These findings suggest that contin-
uous exogenous delivery of PDGF-A may delay mineral
formation induced by cementoblasts, while PDGF is
clearly required for mineral neogenesis.
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